The all-oral, fixed-duration treatment combination provided better PFS and safety than investigator’s choice of chemoimmunotherapy in the phase 3 AMPLIFY study.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/acalabrutinib-venetoclax-combo-earns-fda-nod-cll-2026a10005gy?src=rss
Author :
Publish date : 2026-02-20 21:33:00
Copyright for syndicated content belongs to the linked Source.